According to what stated by the authors and with the inclusion criteria of the study, “the patient population in the trial represents the earliest clinical phase in tumorigenesis of IDH-mutant WHO grade 2 glioma”, or rather patients classified as “low risk” and currently candidate for a “watch and wait” approach. The gene discussed is IDH2; the disease is glioma.